Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration

Summary

This paper reviews the role of mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration, highlighting its pathogenic functions in Alzheimer's disease and its implications for other neurodegenerative conditions, while also discussing potential therapeutic strategies.

Key findings

• mTOR is a critical nutrient sensor with homeostatic functions in neurons.
• Dysregulated mTOR signaling contributes to AD pathogenesis by impairing insulin signaling and autophagy.
• mTORC1 and mTORC2 are implicated in PD, HD, FTD, and ALS.
• mTOR inhibitors, particularly rapalogs, offer potential therapeutic avenues.

Methods

• Review of signaling pathways and homeostatic functions of mTOR.
• Analysis of recent data implicating mTOR in various neurodegenerative diseases.
• Discussion of therapeutic strategies involving mTOR inhibitors (rapamycin and rapalogs).

Limitations

• The abstract does not detail specific experimental methodologies or data.
• The scope is broad, covering multiple neurodegenerative diseases.
• Clinical efficacy of mTOR inhibitors in humans is not elaborated upon in the abstract.

Applications

• Development of novel therapeutic targets for neurodegenerative diseases.
• Potential for early diagnosis and monitoring of neurodegeneration.
• Treatment of Alzheimer's disease, Parkinson's disease, Huntington's disease, FTD, and ALS.